CEO Bradley L. Campbell Cashes Out 20,000 Shares of Amicus Therapeutics Stock

August 12, 2023

Categories: BiotechnologyTags: , , Views: 26

☀️Trending News

Amicus Therapeutics ($NASDAQ:FOLD), Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines to treat rare and orphan diseases. The company is headquartered in Cranbury, New Jersey, and has research and development operations in both the United States and Europe.

Share Price

This news sent the stock price down sharply, as the stock opened at $13.1 and closed at $12.5, a decrease of 4.6% from the prior closing price. The sale was part of an automatic trading plan that was established prior to the sale, allowing for an orderly disposition of shares. Although the stock dipped significantly, Amicus Therapeutics is still well-positioned to continue its strong performance in the future. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Amicus Therapeutics. More…

    Total Revenues Net Income Net Margin
    350.56 -185.31 -51.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Amicus Therapeutics. More…

    Operations Investing Financing
    -126.6 94.07 15.85
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Amicus Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    730.09 618.51 0.39
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Amicus Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    15.6% -42.2%
    FCF Margin ROE ROA
    -38.0% -86.4% -12.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we offer an analysis of AMICUS THERAPEUTICS‘s fundamentals. After conducting a thorough review of their financial statements, we’ve determined that the company’s Risk Rating is medium. This means that they are exposed to a moderate amount of risk in terms of financial and business aspects. We’ve also detected 3 risk warnings in their balance sheet, cashflow statement, and financial journal. These warnings could indicate potential issues with their cash management, budgeting, and overall financial performance. With this in mind, we suggest that you register with us to get a better understanding of the risks associated with investing in AMICUS THERAPEUTICS. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company’s competitors include SpringWorks Therapeutics Inc, Synthetic Biologics Inc, and Tonix Pharmaceuticals Holding Corp.

    – SpringWorks Therapeutics Inc ($NASDAQ:SWTX)

    Springs Works Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of treatments for patients with psychiatric and neurological disorders. The company’s most advanced product candidate is brexanolone, which is in Phase III clinical trials for the treatment of postpartum depression. Springs Works has a market cap of $1.52 billion and a return on equity of -64.67%.

    – Synthetic Biologics Inc ($NYSEAM:SYN)

    The company’s market cap is 28.98M as of 2022 and its ROE is -26.13%. The company’s products include prescription and over-the-counter drugs, as well as medical devices and supplies. The company has operations in the United States, Europe, Asia, and Latin America. The company’s products are sold through a network of retail pharmacies, wholesalers, and distributors.


    The move caused the stock price to drop that same day. This could be interpreted as a signal of lack of confidence in the company’s stock from the CEO. Investors should pay close attention to Amicus Therapeutics stock in the coming days and analyze the impact of this sale to determine if it is a buy or sell opportunity. It is important to remember to do your own research and not rely solely on news headlines.

    Fundamental and technical analysis are key components of any investment decision. Looking at the company’s financials such as revenue, debt, and profit margins can help investors form an informed opinion before investing in Amicus Therapeutics stock.

    Recent Posts

    Leave a Comment